scholarly journals Prevalence and electrophysiological characteristics of typical atrial flutter in patients with atrial fibrillation and chronic obstructive pulmonary disease

EP Europace ◽  
2013 ◽  
Vol 15 (12) ◽  
pp. 1777-1783 ◽  
Author(s):  
T. Hayashi ◽  
S. Fukamizu ◽  
R. Hojo ◽  
K. Komiyama ◽  
Y. Tanabe ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Atrial Flutter ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Typical Atrial Flutter

scholarly journals Frequency of Atrial Arrhythmias in the Patients With Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 15 (7) ◽  
pp. 1693-1696
Author(s):  
M. Mueed Yasin ◽  
A Zeeshan Khan Chachar ◽  
Sajjad Ali ◽  
Sajjad Ali ◽  
Asim M. Khan ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Atrial Flutter ◽  
Atrial Tachycardia ◽  
Chronic Obstructive ◽  
Atrial Arrhythmias ◽  
Cross Sectional ◽  
Obstructive Pulmonary Disease ◽  
Medical Division

Background: Chronic obstructive pulmonary disease (COPD) has been linked with various kind of cardiac arrhythmias. The risk of arrhythmias in patients with COPD has been driven by the stage and disease state, with a higher frequency of supraventricular tachycardia during exacerbations. Aim: To evaluate the frequency of atrial arrhythmias (which include atrial fibrillation, atrial flutter, and multifocal atrial tachycardia) in the patients who were suffering from COPD. Methods: It was a cross sectional analysis or prevalence study. This research was piloted in the Medicine Department, Medical Division IV, Services Hospital, Lahore. This research was ended in 365 days after endorsement of synopsis from 1st June, 2017 to 30th May 2018. Results: In our study, 111(46.25%) were in range 40-55 years of age while 129(53.75%) were in range 56-70 years of age, the calculated mean standard deviation was 56.23±8.19 years, 134(55.83%) were male and 106(44.17%) were females, 142(59.17%) between 1-2 years and 98(40.83%) had >2 years of duration. Frequency of atrial arrhythmias in the patients who were suffering from COPD was recorded as 22(9.17%) having Atrial Fibrillation, 53(22.08%) had Atrial flutter and 31(12.92%) had Multifocal atrial tachycardia. Conclusion: Atrial arrhythmias are common findings in patients with COPD. So, it is very important for treating physicians that every patient having COPD, should undergo Electrocardiogram (ECG) for picking up the atrial arrhythmias. Keywords: Chronic obstructive pulmonary disease, atrial arrhythmias, frequency

The role of beta-agonist therapy for chronic obstructive airway disease in patients with coexistent atrial fibrillation: Literature review

2021 ◽  
Vol 2 (6) ◽  
Author(s):  
Rodríguez Miguel ◽  
◽  
Chinta Siddharth ◽  
Vittorio Timothy ◽  
◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Airway Disease ◽  
The Other ◽  
Beta Agonist ◽  
Beta Blockade ◽  
Chronic Obstructive ◽  
Agonist Therapy ◽  
Obstructive Pulmonary Disease

Background: New advances have been made in medicine, but the incidence and prevalence of Chronic Obstructive Pulmonary Disease (COPD) are evident, and it is established as the fourth cause of death in the United States representing a high cost for the healthcare system. This condition has been related to atrial fibrillation due to the changes in the lungs and vasculature. Based on this history, we seek to evaluate the outcome of AF in the patients with COPD and its relationship with medical therapy utilized to treat this pulmonary condition with the objective of establishing the relationship between the use of beta-agonist therapy for obstructive airway disease in patients with AF. Discussion: Cell receptors participate in multiple reactions and the sympathetic response is received via the alpha- and beta-receptors are related to the hemodynamic of the vasculature of the lungs and cardiovascular system. The beta-blockade agents are one of the most common medication classes used for rate control in cardiac arrhythmias, but the side effect could be COPD exacerbation; on the other hand, beta-adrenergic or beta-agonist as a therapy for this pulmonary condition could increase the heart rate leading to AF decompensation. There is a clear dilemma in our patients who have airway disease and AF since the treatment for one might worsen the other. The clear benefit in morbidity and mortality of beta-blocker therapy, especially beta1-selective, outweighs the potential for any pulmonary side-effects related to ex-acerbation of COPD or airway disease. Conclusion: There is clear data showing the evidence of the potential paradoxical side-effect between COPD and AF therapies, given the exacerbation of one due to treatment of the other, benefits versus risks should be discussed and the medical decision should be made based on them. The deteriorated cardiac condition can rapidly predispose to critical complications leading to death, which is why the use of beta-blockade agents will be chosen over possible complications with pulmonary disease. In other words, the benefit should outweigh the risk based on the best outcome for the patient. Keywords: atrial fibrillation; pulmonary disease; obstructive pulmonary disease; chronic obstructive pulmonary disease (COPD); B-Agonist; B-Block (selective; non-selective); digitalis; other antiarrhythmic.

scholarly journals ATRIAL FIBRILLATION IN COMORBID PATIENTS DEPENDING ON THE TREATMENT REGIMEN

2019 ◽  
Vol 8 (2) ◽  
pp. 21-29 ◽  
Author(s):  
L. D. Khidirova ◽  
D. A. Yakhontov ◽  
S. A. Zenin
Keyword(s):  
Diabetes Mellitus ◽  
Atrial Fibrillation ◽  
Chronic Obstructive Pulmonary Disease ◽  
Arterial Hypertension ◽  
Pulmonary Disease ◽  
Abdominal Obesity ◽  
Blood Pressure Monitoring ◽  
Clinical Status ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

Aim. To study the clinical course of atrial fibrillation in patients with arterial hypertension and extracardiac comorbid pathology depending on the administered therapy.Methods. 207 men aged 45–65 years with atrial fibrillation (paroxysmal and persistent) and arterial hypertension in combination with diabetes mellitus (n = 40), abdominal obesity (n = 64) and chronic obstructive pulmonary disease (n = 47) were recruited to a observational cohort study. 56 patients with atrial fibrillation and arterial hypertension but without any extracardiac diseases were included in the comparison group. Clinical and anthropometric parameters were assessed in all patients. Adherence to therapy was estimated with the Morisky-Green test. All patients underwent ECG; electrocardiographic holter monitoring, 24-hour blood pressure monitoring with the Daily Monitoring Systems SCHILLER (Schiller, Switzerland), 2D and M-mode echocardiography using a Vivid 7 device (General Electric, USA). The statistical analysis was performed in the Rstudio software (version 0.99.879, RStudio, Inc., MA, USA).Results. 66% of patients with atrial fibrillation and arterial hypertension had concomitant extracardiac comorbid pathology, of them 20% of had diabetes mellitus, 22% with chronic obstructive pulmonary disease, and 24% with abdominal obesity. The clinical groups were comparable in electro impulse and drug therapy. Patients who received medical treatment were frequently admitted to hospitals for atrial fibrillation recurrence (p<0.001), compared with those who underwent electro impulse therapy. Adherence to antiarrhythmic therapy was low in the entire cohort of patients. There were no significant differences found between the clinical groups.Conclusion. Early diagnosis of the factors contributing to the progression of AF, the prescription of additional therapy for the secondary prevention of arrhythmia and the choice of its optimal treatment strategy may slow the progression of arrhythmia and the development of CHF, which will improve not only the clinical status of patients, but also their prognosis.

Atrial fibrillation and sleep apnoea and chronic obstructive pulmonary disease

ESC CardioMed ◽  
2018 ◽  
pp. 2235-2237
Author(s):  
Tauseef Akhtar ◽  
Jared D. Miller ◽  
Hugh Calkins
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Risk Factor Modification ◽  
Obstructive Sleep ◽  
P Rate

Rate control, rhythm control, and anticoagulation are well entrenched as the three central pillars of atrial fibrillation (AF) management. Risk factor modification of other associated co-morbidities is now emerging as a critical fourth pillar in the prevention and management of AF. Obstructive sleep apnoea and chronic obstructive pulmonary disease, in particular, have important implications in the development of AF and appropriate selection of therapy. This chapter reviews the pathophysiology and clinical evidence linking these conditions with AF. In addition, it discusses important considerations in the management of concurrent AF and obstructive sleep apnoea or chronic obstructive pulmonary disease.

Atrial fibrillation and sleep apnoea and chronic obstructive pulmonary disease

ESC CardioMed ◽  
2018 ◽  
pp. 2235-2237
Author(s):  
Jared D. Miller ◽  
Hugh G. Calkins
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Risk Factor Modification ◽  
Obstructive Sleep ◽  
P Rate

Rate control, rhythm control, and anticoagulation are well entrenched as the three central pillars of atrial fibrillation (AF) management. Risk factor modification of other associated co-morbidities is now emerging as a critical fourth pillar in the prevention and management of AF. Obstructive sleep apnoea and chronic obstructive pulmonary disease, in particular, have important implications in the development of AF and appropriate selection of therapy. This chapter reviews the pathophysiology and clinical evidence linking these conditions with AF. In addition, it discusses important considerations in the management of concurrent AF and obstructive sleep apnoea or chronic obstructive pulmonary disease.

Sign in / Sign up

Export Citation Format

Share Document